Towards prevention of type 1 diabetes: FDA approved first drug with potential to delay clinical stage of disease
https://doi.org/10.14341/DM12988
Abstract
Given the increased morbidity and mortality in patients with type 1 diabetes mellitus (T1DM), as well as the burden posed by the disease, the search for methods to prevent the destruction of beta cells is of paramount importance. Until recently, no attempts of immunotherapeutic interventions have achieved significant success, allowing at best reducing the rate of destruction of beta cells without stopping the immune process and not allowing normalization of glycemia. In November 2022, the U.S. Food and Drug Administration (FDA) approved the drug teplizumab to delay clinical diagnosis of T1DM. The purpose of the publication is to evaluate the results of teplizumab treatment in high-risk participants with the second (preclinical) stage of T1DM, as well as to consider further prospects for this treatment.
About the Authors
D. N. Laptev
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Dmitry N. Laptev, MD, PhD
Researcher ID: O-1826-2013; Scopus Author ID: 24341083800; eLibrary SPIN: 2419-4019
11, Dm. Ul’yanova street, 117036 Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
I. I. Dedov
Endocrinology Research Centre
Russian Federation
Competing Interests:
Russian Federation
Ivan I. Dedov, MD, PhD, Professor, Academician of the Russian Academy of Sciences
Researcher ID: D-3729-2014; Scopus Author ID: 7101843976; eLibrary SPIN: 5873-2280
Moscow
Competing Interests:
Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с содержанием настоящей статьи.
References
1. FDA Approves First Drug That Can Delay Onset of Type 1 Diabetes. Available at: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes Accessed November 18, 2022.
2. Herold KC, Bundy BN, Long SA, et al. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. N Engl J Med. 2019;381(7):603-613. doi: https://doi.org/10.1056/NEJMoa1902226
3. Sims EK, Bundy BN, Stier K, et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021;13(583):eabc8980. doi: https://doi.org/10.1126/scitranslmed.abc8980
4. Waldron-Lynch F, Henegariu O, Deng S, et al. Teplizumab Induces Human Gut-Tropic Regulatory Cells in Humanized Mice and Patients. Sci Transl Med. 2012;4(118). doi: https://doi.org/10.1126/scitranslmed.3003401
5. Esplugues E, Huber S, Gagliani N, et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475(7357):514-518. doi: https://doi.org/10.1038/nature10228
6. Dedov II, Shestakova MV. Type 1 diabetes mellitus: realities and prospects. Moscow: OOO Publishing House Medical Information Agency, 2016. 504 p. (In Russ.).
7. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet Lond Engl. 2014;383(9911):69-82. doi: https://doi.org/10.1016/S0140-6736(13)60591-7
8. Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes. 2013;62(11):3766-3774. doi: https://doi.org/10.2337/db13-0345
9. Lord S, Greenbaum CJ. Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. F1000Research. 2020;9:827. doi: https://doi.org/10.12688/f1000research.21801.1
10. Hagopian W, Ferry RJ, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes. 2013;62(11):3901-3908. doi: https://doi.org/10.2337/db13-0236
11. Insel RA, Dunne JL, Atkinson MA, et al. Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974. doi: https://doi.org/10.2337/dc15-1419
12. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol Baltim Md 1950. 1997;158(6):2947-2954.
13. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;362(15):1383-1395. doi: https://doi.org/10.1056/NEJMoa0904492
14. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet Lond Engl. 2008;372(9636):375-382. doi: https://doi.org/10.1016/S0140-6736(08)61000-4
15. Tucker ME. With Type 1 Diabetes Delay Possible, Focus Now on Screening. Available at: www.medscape.com. Published November 30, 2022. Accessed November 30, 2022.
Review
For citations:
Laptev D.N., Dedov I.I. Towards prevention of type 1 diabetes: FDA approved first drug with potential to delay clinical stage of disease. Diabetes mellitus. 2022;25(6):576-579. (In Russ.) https://doi.org/10.14341/DM12988
Views:
8877
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
